MedPage Today—December 18, 2014
A comprehensive, long-term analysis of certolizumab pegol (CZP) in randomized trials involving rheumatoid arthritis (RA) patients has uncovered no new or unexpected safety signals.
The analysis found no increases in rates of adverse events, serious adverse events, or serious infectious events with prolonged exposure to certolizumab, with the new data being in line with previously reported safety data and with other biologics, including tumor necrosis factor inhibitors, according to Vivian P. Bykerk, MD of the Inflammatory Arthritis Center at Hospital for Special Surgery in New York City, and colleagues.
CZP is a pegylated Fc-free TNF inhibitor approved for adult patients with moderate to severe active RA. The drug also has a positive impact in Crohn's disease, psoriasis, psoriatic arthritis, and axial spondyloarthritis. About 47,000 patients worldwide are believed to be receiving CZP.
Read the full story at medpagetoday.com.
212.606.1197
mediarelations@hss.edu